APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Vincent Hospital
Fitzroy, Victoria, Australia
Masa Lasica, MDRecruiting - Epworth Healthcare
Richmond, Victoria, Australia
Costas Yannakou, MDRecruiting
- Mayo Clinic
Jacksonville, Florida, United States
sikander ailawdhi, mdRecruiting - Duke Unviersity
Durham, North Carolina, United States
Completed - Mdacc
Houston, Texas, United States
Tapan Kadia, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Aug 2018
- Primary completion
- 15 Sept 2024
- Completion
- 15 Feb 2025
- Last update posted
- 19 Aug 2024
- Registered enrollment
- 90
- Registry id
- NCT03537482
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.